Literature DB >> 23925655

HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions.

Daniele Fanale1, Viviana Bazan, Lidia Rita Corsini, Stefano Caruso, Lavinia Insalaco, Marta Castiglia, Giuseppe Cicero, Giuseppe Bronte, Antonio Russo.   

Abstract

Numerous microarray-based gene expression studies performed on several types of solid tumors revealed significant changes in key genes involved in progression and regulation of the cell cycle, including AURKA that is known to be overexpressed in many types of human malignancies. Tumor hypoxia is associated with poor prognosis in several cancer types, including breast cancer (BC). Since hypoxia is a condition that influences the expression of many genes involved in tumorigenesis, proliferation, and cell cycle regulation, we performed a microarray-based gene expression analysis in order to identify differentially expressed genes in BC cell lines exposed to hypoxia. This analysis showed that hypoxia induces a down-regulation of AURKA expression. Although hypoxia is a tumor feature, the molecular mechanisms that regulate AURKA expression in response to hypoxia in BC are still unknown. For the first time, we demonstrated that HIF-1 activation downstream of hypoxia could drive AURKA down-regulation in BC cells. In fact, we found that siRNA-mediated knockdown of HIF-1α significantly reduces the AURKA down-regulation in BC cells under hypoxia. The aim of our study was to obtain new insights into AURKA transcriptional regulation in hypoxic conditions. Luciferase reporter assays showed a reduction of AURKA promoter activity in hypoxia. Unlike the previous findings, we hypothesize a new possible mechanism where HIF-1, rather than inducing transcriptional activation, could promote the AURKA down-regulation via its binding to hypoxia-responsive elements into the proximal region of the AURKA promoter. The present study shows that hypoxia directly links HIF-1 with AURKA expression, suggesting a possible pathophysiological role of this new pathway in BC and confirming HIF-1 as an important player linking an environmental signal to the AURKA promoter. Since AURKA down-regulation overrides the estrogen-mediated growth and chemoresistance in BC cells, these findings could be important for the development of new possible therapies against BC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23925655     DOI: 10.1007/s10549-013-2649-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  17 in total

1.  Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.

Authors:  Han Zhang; Zheng Chen; Roberto N Miranda; L Jeffrey Medeiros; Nami McCarty
Journal:  Blood       Date:  2017-06-07       Impact factor: 22.113

2.  Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4.

Authors:  Karuna Mittal; Jaspreet Kaur; Shaligram Sharma; Nivya Sharma; Guanhao Wei; Ishita Choudhary; Precious Imhansi-Jacob; Nagini Maganti; Shrikant Pawar; Padmashree Rida; Michael S Toss; Mohammed Aleskandarany; Emiel A Janssen; Håvard Søiland; Meenakshi V Gupta; Michelle D Reid; Emad A Rakha; Ritu Aneja
Journal:  Mol Cancer Res       Date:  2022-04-01       Impact factor: 6.333

3.  β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma.

Authors:  Ruhee Dere; Ashley Lyn Perkins; Tasneem Bawa-Khalfe; Darius Jonasch; Cheryl Lyn Walker
Journal:  J Am Soc Nephrol       Date:  2014-10-13       Impact factor: 10.121

Review 4.  Dietary restriction: could it be considered as speed bump on tumor progression road?

Authors:  Antonina Cangemi; Daniele Fanale; Gaetana Rinaldi; Viviana Bazan; Antonio Galvano; Alessandro Perez; Nadia Barraco; Daniela Massihnia; Marta Castiglia; Salvatore Vieni; Giuseppe Bronte; Mario Mirisola; Antonio Russo
Journal:  Tumour Biol       Date:  2016-04-04

5.  Methylation Landscape of Human Breast Cancer Cells in Response to Dietary Compound Resveratrol.

Authors:  Rubiceli Medina-Aguilar; Carlos Pérez-Plasencia; Laurence A Marchat; Patricio Gariglio; Jaime García Mena; Sergio Rodríguez Cuevas; Erika Ruíz-García; Horacio Astudillo-de la Vega; Jennifer Hernández Juárez; Ali Flores-Pérez; César López-Camarillo
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

6.  Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

Authors:  Daniele Fanale; Valeria Amodeo; Viviana Bazan; Lavinia Insalaco; Lorena Incorvaia; Nadia Barraco; Marta Castiglia; Sergio Rizzo; Daniele Santini; Antonio Giordano; Sergio Castorina; Antonio Russo
Journal:  Oncotarget       Date:  2016-05-17

Review 7.  Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway.

Authors:  Laura La Paglia; Angela Listì; Stefano Caruso; Valeria Amodeo; Francesco Passiglia; Viviana Bazan; Daniele Fanale
Journal:  PPAR Res       Date:  2017-01-15       Impact factor: 4.964

Review 8.  Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.

Authors:  Daniela Massihnia; Antonio Galvano; Daniele Fanale; Alessandro Perez; Marta Castiglia; Lorena Incorvaia; Angela Listì; Sergio Rizzo; Giuseppe Cicero; Viviana Bazan; Sergio Castorina; Antonio Russo
Journal:  Oncotarget       Date:  2016-09-13

Review 9.  A new aurora in anaplastic thyroid cancer therapy.

Authors:  Enke Baldini; Massimino D'Armiento; Salvatore Ulisse
Journal:  Int J Endocrinol       Date:  2014-07-01       Impact factor: 3.257

10.  Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus.

Authors:  Daniela Cabibi; Stefano Caruso; Viviana Bazan; Marta Castiglia; Giuseppe Bronte; Sabrina Ingrao; Daniele Fanale; Antonina Cangemi; Valentina Calò; Angela Listì; Lorena Incorvaia; Antonio Galvano; Gianni Pantuso; Eugenio Fiorentino; Sergio Castorina; Antonio Russo
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.